Chrome Extension
WeChat Mini Program
Use on ChatGLM
VIPCreated with Sketch.

No Evidence of Disease Activity (NEDA-3) and Disability Improvement after Alemtuzumab Treatment for Multiple Sclerosis: a 36-Month Real-World Study

Luca Prosperini,Pietro Annovazzi,Laura Boffa,Maria Chiara Buscarinu,Antonio Gallo,Manuela Matta,Lucia Moiola,Luigina Musu,Paola Perini,Carlo Avolio,Valeria Barcella,Assunta Bianco,Deborah Farina,Elisabetta Ferraro,Simona Pontecorvo,Franco Granella,Luigi M. E. Grimaldi,Alice Laroni,Giacomo Lus,Francesco Patti,Eugenio Pucci,Matteo Pasca,Paola Sarchielli, the Italian Alemtuzumab Study Group

Journal of Neurology（2018）

Cited 47|Views86
Key words
Multiple sclerosis,Alemtuzumab,Outcome measurement
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined